U.S. Food and Drug Administration (FDA) Accepts Tevas New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults
Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the…
Pluristyx and Solesis Launch First-of-its-Kind PluriForm-GFP-3D Transfection Kit, Solving Critical Bottlenecks in Suspension Culture Transfection
New ready-to-use kit combines Pluristyx’s high-quality pluripotent cells and mRNA technology with…
FDA Approves Expanded Indication for UZEDY (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy…
